(Q38175870)

30 August 2017

title

Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz (English)

1 reference

30 August 2017

1 reference

Panjasaram Naidoo

1

1 reference

30 August 2017

Vasudevan V Chetty

series ordinal

2

1 reference

30 August 2017

Manoranjenni Chetty

series ordinal

3

1 reference

30 August 2017

publication date

5 January 2014

1 reference

European Journal of Clinical Pharmacology

30 August 2017

published in

1 reference

30 August 2017

volume

70

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

379-389

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-013-1634-1

30 August 2017

exact match

0 references

cites work

Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Polymorphism of human cytochrome P450 enzymes and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Cytochrome P450 pharmacogenetics in African populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Sex differences in pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Efavirenz in the therapy of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Transporter-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Drug interactions between antiretroviral drugs and comedicated agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Cytochrome P450 2B6: function, genetics, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1634-1

Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz

21 January 2018

1 reference

12 December 2020

CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans

1 reference

12 December 2020

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

12 December 2020

The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies

1 reference

12 December 2020

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

1 reference

12 December 2020

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

1 reference

12 December 2020

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

1 reference

12 December 2020

Overview of the pharmacogenetics of HIV therapy.

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Efavirenz in the management of HIV infection

1 reference

12 December 2020

Population pharmacokinetic meta-analysis with efavirenz

1 reference

12 December 2020

Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers.

1 reference

12 December 2020

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance

1 reference

12 December 2020

Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

1 reference

12 December 2020

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

12 December 2020

10.1007/S00228-013-1634-1

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1026997456

0 references

1 reference